, Volume 24, Issue 1, pp 64–68 | Cite as

Azithromycin and doxycycline for treatment ofBorrelia culture-positive erythema migrans

  • F. Strle
  • J. Cimperman
  • Vera Maraspin
  • Stanka Lotric-Furlan
  • Eva Ruźić-Sabljić
Special Addendum — Part I Therapy And Prophylaxis In Lyme Borreliosis


Adult patients with typical solitary erythema migrans, participating in prospective therapeutic studies on early Lyme borreliosis at the Lyme borreliosis Outpatient's Clinic, University Department of Infectious Diseases in Ljubljana, in 1991 to 1993, and followed up for 1 year, were included in the study. Only patients who were treated with azithromycin or doxycycline and in whomBorrelia burgdorferi was isolated from the border of the skin lesion prior to institution of antibiotic treatment were selected for presentation in this report. Fifty-eight patients received azithromycin (500 mg twice daily for the first day, followed by 500 mg once daily for 4 days) and 42 patients received doxycycline (100 mg twice daily for 14 days). The median duration of skin lesions after the beginning of treatment was 6.5 (2–30) days in the azithromycin group and 8 (2–35) days in the doxycycline group (nonsignificant difference). During the follow-up of 12 months one patient in each group developed major later manifestations of Lyme borreliosis and in 19 patients minor manifestations appeared: in nine (15.5%) treated with azithromycin and in ten (23.8%) receiving doxycycline. In one patient in the azithromycin group and in one patient in the doxycycline groupB. burgdorferi was isolated from normal appearing skin at the site of previous erythema migrans 2 months after the institution of antibiotic therapy. Five (8.6%) patients receiving azithromycin and nine (21.4%) patients receiving doxycycline reported mild to moderate gastrointestinal discomfort. In addition, five patients treated with doxycycline developed photosensitivity.


Doxycycline Azithromycin Lyme Borreliosis Erythema Migrans Azithromycin Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Azithromycin und Doxycyclin in der Therapie der kulturell nachgewiesenen Borrelieninfektion mit Erythema migrans


In der vorliegenden Studie wurden erwachsene Patienten mit typischem solitären Erythema migrans, die an prospektiven Studien zur Behandlung der frühen Lyme-Borreliose an der Lyme-Borreliose-Ambulanz der Universitätsklinik Ljubljana, Abteilung für Infektionskrankheiten teilnahmen und ein Jahr lang nachbeobachtet wurden, aufgenommen. Im folgenden wird nur über die Patienten berichtet, bei denenBorrelia burgdorferi aus dem Rand der Hautläsion isoliert worden war, bevor eine Behandlung mit Azithromycin oder Doxycyclin eingeleitet wurde. 58 Patienten erhielten Azithromycin (500 mg zweimal täglich am ersten Tag, anschließend 500 mg einmal täglich für 4 Tage). 42 Patienten wurden mit Doxycyclin in einer Dosis von zweimal täglich 100 mg 14 Tage lang behandelt. Nach Einleitung der Therapie blieben die Hautläsionen in der Azithromycin-Gruppe im Median 6.5 (2–30) Tage, in der Doxycyclin-Gruppe 8 (2–35) Tage bestehen (Unterschied nicht signifikant). Während der 12monatigen Verlaufsbeobachtung entwickelte aus jeder Gruppe ein Patient schwerwiegende Folgeerscheinungen der Lyme-Borreliose, in 19 Fällen kam es zu geringfügigeren Manifestationen. Neun Fälle (15,5%) traten nach Behandlung mit Azithromycin und zehn (23,8%) nach Behandlung mit Doxycyclin auf. Bei je einem Patienten der Azithromycin und Doxycyclin-Gruppe wurdeB. burgdorferi aus augenscheinlich normaler Haut an der Stelle der früheren Erythema migrans-Läsion 2 Monate nach Einleitung der Antibiotikatherapie isoliert. Fünf Patienten (8,6%) berichteten unter Azithromycin und neun Patienten (21,4%) unter Doxycyclin über leichte bis mäßiggradige gastrointestinale Beschwerden. Zusätzlich trat bei fünf mit Doxycyclin behandelten Patienten eine Photosensitivität auf.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Burgdorfer, W., Barbour, A. G., Hayes, S. F., Benach, L. J., Grunwaldt, E., Davis, J. P. Lyme disease: a tick-borne spirochetosis? Science 216 (1982) 1317–1319.PubMedGoogle Scholar
  2. 2.
    Stanek, G., Satz, N., Strle, F., Wilske, B. Epidemiology of Lyme borreliosis. In:Weber, K., Burgdorfer, W. (eds.): Aspects of Lyme borreliosis. Springer-Verlag, Berlin Heidelberg 1993, pp. 358–370.Google Scholar
  3. 3.
    Ciesielski, C. A., Markowitz, L. E., Horsley, R., Hightower, A. W., Russell, H., Broome, C. V. The geographic distribution of Lyme disease in the United States. Ann. N. Y. Acad. Sci. 539 (1988) 283–288.PubMedGoogle Scholar
  4. 4.
    Asbrink, E., Olsson, I., Hovmark, A. Erythema chronicum migrans Afzelius in Sweden: A study on 231 patients. Zbl. Bakt. Hyg. A 263 (1986) 229–236.Google Scholar
  5. 5.
    Steere, A. C. Lyme disease. N. Engl. J. Med. 321 (1989) 586–596.PubMedGoogle Scholar
  6. 6.
    Preac-Mursic, V., Wilske, B., Schierz, B., Holburger, M., Suss, E. In vitro andin vivo susceptibility ofBorrelia burgdorferi. Eur. J. Clin. Microbiol. 6 (1987) 424–426.PubMedGoogle Scholar
  7. 7.
    Johnson, R. C., Kodner, C., Russell, M., Duray, H. P. Experimental infection of hamsters withBorrelia burgdorferi. Ann. N. Y. Acad. Sci. 539 (1988) 258–263.PubMedGoogle Scholar
  8. 8.
    Preac-Mursic, V., Wilske, B., Schierz, G., Suss, E., Gross, B. Comparative antimicrobial activity of the new macrolides againstBorrelia burgdorferi. Eur. J. Clin. Microbiol. 8 (1989) 651–653.Google Scholar
  9. 9.
    Johnson, E. C., Kodner, C., Russell, M., Girard, D. In vitro andin vivo susceptibility ofBorrelia burgdorferi to azithromycin. J. Antimicrob. Chemother. 25 (Suppl. A) (1990) 33–38.Google Scholar
  10. 10.
    Wretlind, B., Johnson, R. C., Hansen, K., Preac-Mursic, V. Antibiotic susceptibility ofBorrelia burgdorferi inin vitro and in animal models. Scand. J. Infect. Dis. Suppl. 77 (1991) 143–144.PubMedGoogle Scholar
  11. 11.
    Preac-Mursic, V. Antibiotic susceptibility ofBorrelia burgdorferi in vitro andin vivo. In:Weber, K., Burgdorfer, W. (eds.): Aspects of Lyme borreliosis. Springer-Verlag, Berlin Heidelberg 1993, pp. 301–311.Google Scholar
  12. 12.
    Massarotti, E. M., Luger, S. W., Rahn, D. W., Messner, R. P., Wong, J. B., Johnson, R. C., Steere, A. C. Treatment of early Lyme disease. Am. J. Med. 92 (1992) 396–403.PubMedGoogle Scholar
  13. 13.
    Strle, F., Ružić, E., Cimperman, J. Erythema migrans: comparison of treatment with azithromycin, doxycycline and phenoxymethylpenicillin. J. Antimicrob. Chemother. 30 (1992) 543–550.PubMedGoogle Scholar
  14. 14.
    Strle, F., Preac-Mursic, V., Cimperman, J., Ružić, E., Maraspin, V., Jereb, M. Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiological findings. Infection 21 (1993) 83–88.PubMedGoogle Scholar
  15. 15.
    Weber, K., Wilske, B., Preac-Mursic, V., Thurmayr, R. Azithromycin versus penicillin V for treatment of early Lyme borreliosis. Infection 21 (1993) 367–372.PubMedGoogle Scholar
  16. 16.
    Luft, B. J., Luger, S. W., Rahn, D. W., Dattwyler, R. J., Gadgil, S. D.: Azithromycin and amoxicillin for the treatment of erythema migrans. Preliminary analysis of the double blind trial. In: Proceedings and abstracts of the Vth International Conference on Lyme borreliosis, Arlington, Bethesda, MD: Fed. Am. Soc. Exp. Biol., 1992, abstract no. 56.Google Scholar
  17. 17.
    Dattwyler, R., Luft, B., Johnson, R., and the Azithromycin Study Group: Serologic response toBorrelia burgdorferi in patients with erythema migrans: the effect of treatment. In: Advances in Lyme borreliosis. Proceedings of the VIth International Conference on Lyme borreliosis, Bologna, Italy, 1994, pp. 136–139.Google Scholar
  18. 18.
    Steere, A. C., Hutchinson, G. J., Rahn, D. W. A., Sigal, L. H., Craft, J. E., DeSanna, E. T., Malawista, S. E. Treatment of the early manifestations of Lyme disease. Ann. Intern. Med. 99 (1983) 22–26.PubMedGoogle Scholar
  19. 19.
    Preac-Mursic, V., Wilske, B., Schierz, G. EuropeanBorrelia burgdorferi isolated from humans and ticks. Culture conditions and antibiotic susceptibility. Zbl. Bakt. Hyg. A 263 (1986) 112–118.Google Scholar
  20. 20.
    Girard, A. E., Girard, D., Retsema, J. A. Correlation of the extravascular pharmacokinetics of azithromycin within vivo efficacy in models of localized infection. J. Antimicrob. Chemother. 25 (Suppl. A) (1990) 49–60.Google Scholar
  21. 21.
    Foulds, G., Shepard, R. M., Johnson, R. B. The pharmacokinetics of azithromycin in human serum and tissues. J. Antimicrob. Chemother. 25 (Suppl. A) (1990) 73–82.Google Scholar
  22. 22.
    McDonald, P. J., Pruul, H. Phagocyte uptake and transport of azithromycin. Eur. J. Clin. Microbiol. Infect. Dis. 10 (1991) 828–833.PubMedGoogle Scholar
  23. 23.
    Marconi, R. T., Garon, C. F. Phylogenetic analyses of the genusBorrelia: a comparison of North American and European isolates ofBorrelia burgdorferi. J. Bacteriol. 174 (1992) 241–244.PubMedGoogle Scholar
  24. 24.
    Welsh, J., Pretzman, C., Postic, D., Saint Girons, I., Baranton, G., McClellad, M. Genomic fingerprinting by arbitrary primed polymerase chain reaction resolvesBorrelia burgdorferi into three distinct phyletic groups. Int. J. Syst. Bacteriol. 42 (1992) 370–377.PubMedGoogle Scholar
  25. 25.
    Peter, O., Bretz, A. G.: In vitro susceptibility ofBorrelia burgdorferi; Borrelia garinii andBorrelia afzelii to 7 antimicrobial agents. In: Advances in Lyme borreliosis research. Proceedings of the VIth International Conference on Lyme borreliosis, Bologna, Italy, 1994, pp. 167–170.Google Scholar
  26. 26.
    Baradaran-Dilmaghani, R., Stanek, G.: In vitro sensitivity of strains of the speciesBorrelia burgdorferi sensu stricto, B. afzelii, andB. garinii against eight antimicrobial chemotherapeutics. In: Program and abstracts of the VIth International Conference on Lyme borreliosis, Bologna, Italy, 1994, abstract no. P078W.Google Scholar

Copyright information

© MMV Medizin Verlag GmbH 1996

Authors and Affiliations

  • F. Strle
    • 1
  • J. Cimperman
    • 1
  • Vera Maraspin
    • 1
  • Stanka Lotric-Furlan
    • 1
  • Eva Ruźić-Sabljić
    • 2
  1. 1.Dept. of Infectious DiseasesUniversity Medical Centre LjubljanaJaplijeva 2
  2. 2.Institute for MicrobiologyUniversity of LjubljanaLjubljanaSlovenia

Personalised recommendations